163 related articles for article (PubMed ID: 7520137)
1. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline protects against both AMPA and kainate-induced lesions in rat striatum in vivo.
Massieu L; Tapia R
Neuroscience; 1994 Apr; 59(4):931-8. PubMed ID: 7520137
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of NBQX on the distal and local toxicity of glutamate agonists administered intra-hippocampally.
Lees GJ; Leong W
Brain Res; 1993 Nov; 628(1-2):1-7. PubMed ID: 7508807
[TBL] [Abstract][Full Text] [Related]
3. Neuronal damage induced by beta-N-oxalylamino-L-alanine, in the rat hippocampus, can be prevented by a non-NMDA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline.
Willis CL; Meldrum BS; Nunn PB; Anderton BH; Leigh PN
Brain Res; 1993 Nov; 627(1):55-62. PubMed ID: 7507397
[TBL] [Abstract][Full Text] [Related]
4. Excitotoxic effects of non-NMDA receptor agonists in organotypic corticostriatal slice cultures.
Kristensen BW; Noraberg J; Jakobsen B; Gramsbergen JB; Ebert B; Zimmer J
Brain Res; 1999 Sep; 841(1-2):143-59. PubMed ID: 10546997
[TBL] [Abstract][Full Text] [Related]
5. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466).
Parsons CG; Gruner R; Rozental J
Neuropharmacology; 1994 May; 33(5):589-604. PubMed ID: 7523977
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of the neuroprotective properties of competitive and uncompetitive N-methyl-D-aspartate receptor antagonists in vivo: implications for the process of excitotoxic degeneration and its therapy.
Massieu L; Thedinga KH; McVey M; Fagg GE
Neuroscience; 1993 Aug; 55(4):883-92. PubMed ID: 7694181
[TBL] [Abstract][Full Text] [Related]
7. NBQX prevents contralateral but not ipsilateral seizure-induced cytotoxicity of kainate but not AMPA-reversal at high doses of NBQX.
Lees GJ; Leong W
Neuroreport; 1994 Oct; 5(16):2153-6. PubMed ID: 7532455
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of non-NMDA subtypes of glutamate receptor in the neonatal rat hemisected spinal cord in vitro.
Zeman S; Lodge D
Br J Pharmacol; 1992 Jun; 106(2):367-72. PubMed ID: 1382781
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation.
Foster AC; Gill R; Woodruff GN
J Neurosci; 1988 Dec; 8(12):4745-54. PubMed ID: 2904493
[TBL] [Abstract][Full Text] [Related]
10. Dizocilpine maleate, MK-801, but not 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline, NBQX, prevents transneuronal degeneration of nigral neurons after neurotoxic striatal-pallidal lesion.
DeGiorgio LA; DeGiorgio N; Volpe BT
Neuroscience; 1999 Apr; 90(1):79-85. PubMed ID: 10188935
[TBL] [Abstract][Full Text] [Related]
11. Non-NMDA antagonists protect against kainate more than AMPA toxicity in the rat hippocampus.
Moncada C; Arvin B; Le Peillet E; Meldrum BS
Neurosci Lett; 1991 Dec; 133(2):287-90. PubMed ID: 1816508
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic and GABAergic postsynaptic responses of striatal spiny neurons to intrastriatal and cortical stimulation recorded in slice preparations.
Kita H
Neuroscience; 1996 Feb; 70(4):925-40. PubMed ID: 8848174
[TBL] [Abstract][Full Text] [Related]
13. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage.
Benavides J; Fage D; Carter C; Scatton B
Brain Res; 1987 Sep; 421(1-2):167-72. PubMed ID: 2891401
[TBL] [Abstract][Full Text] [Related]
14. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
[TBL] [Abstract][Full Text] [Related]
15. Effects of glutamate receptor agonists and antagonists on Ca2+ uptake in rat hippocampal slices lesioned by glucose deprivation or by kainate.
Alici K; Gloveli T; Schmitz D; Heinemann U
Neuroscience; 1997 Mar; 77(1):97-109. PubMed ID: 9044378
[TBL] [Abstract][Full Text] [Related]
16. Complex pharmacological properties of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes.
Stein E; Cox JA; Seeburg PH; Verdoorn TA
Mol Pharmacol; 1992 Nov; 42(5):864-71. PubMed ID: 1279377
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic and ionotropic excitatory amino acid receptor agonists induce different behavioral effects in mice.
Laudrup P; Klitgaard H
Eur J Pharmacol; 1993 Nov; 250(1):15-22. PubMed ID: 7509749
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of extracellular glutamate by inhibition of its uptake is not sufficient for inducing neuronal damage: an in vivo microdialysis study.
Massieu L; Morales-Villagrán A; Tapia R
J Neurochem; 1995 May; 64(5):2262-72. PubMed ID: 7722511
[TBL] [Abstract][Full Text] [Related]
19. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia.
Sheardown MJ; Nielsen EO; Hansen AJ; Jacobsen P; Honoré T
Science; 1990 Feb; 247(4942):571-4. PubMed ID: 2154034
[TBL] [Abstract][Full Text] [Related]
20. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia.
Gill R
Cerebrovasc Brain Metab Rev; 1994; 6(3):225-56. PubMed ID: 7529037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
